Asthma {#s1}
======

Asthma is one of the most common inflammatory diseases globally yet it has been defined by quite broad definitions, such as breathlessness and wheezing, that are associated with variable airflow obstruction and inflammation within the lungs \[[@C1]\]. It becomes increasingly clear that asthma shows a high degree of heterogeneity \[[@C2]\]. Nevertheless, treatment strategies for asthma are largely non-specific, commonly including glucocorticosteroids and bronchodilators. Although most patients respond well to this therapy, a remaining group of asthmatic patients does not respond to the available treatments, accounting for a great part of the economic and health burden of the disease \[[@C3]\]. Furthermore, diagnosis and/or treatment of unresponsiveness to therapy or severity of asthma often does not take into account the various underlying pathological processes, mostly due to the limited information available on how to correlate clinical phenotypes to biological endotypes \[[@C4], [@C5]\].

In a study by B[igler]{.smallcaps} *et al*. \[[@C6]\], nearly 1700 genes were found to be differently expressed in blood samples from severe asthma patients compared to non-asthmatic individuals. In asthmatic patients, pathway analysis showed specific immune cell patterns such as upregulation of genes associated with eosinophils and neutrophils and decreased expression of genes involved in blood-lymphocyte development and haematopoietic progenitor cells. Interestingly, cluster analysis showed subgroups within the severe asthma group who differed in their response to treatment with corticosteroids \[[@C6]\]. At this year\'s congress, A[ffleck]{.smallcaps} *et al.* \[[@C7]\] presented a sequential study comparing blood transcriptomic profiles of adults and children from the U-BIOPRED study with the aim of investigating if a similar dysregulation would be seen in children with asthma. They reported that while the school-aged children showed some differentially expressed gene (DEG) overlap with the adults they were distinct in many pathways, indicating that childhood and adult asthma may be mechanistically different \[[@C7]\].

Indeed, age of disease onset is a significant discriminating factor between different asthma phenotypes and an important factor in severe asthma \[[@C8]\]. In a recent study by H[ekking]{.smallcaps} *et al*. \[[@C9]\], gene set variation analysis was used to identify gene profiles associated with adult-onset severe asthma. This study compared adult-onset with childhood-onset severe asthmatics from the U-BIOPRED cohort using samples from nasal and bronchial brushings, induced sputum and endobronchial biopsies. Gene signatures related to airway inflammation characterised by eosinophils, mast cells and innate lymphocyte cells (ILCs) of Group 3 (ILC3s) were enriched in adult-onset severe asthma. The study by H[ekking]{.smallcaps} *et al*. \[[@C9]\] also showed that in childhood-onset severe asthma, signatures associated with lung damage were more pronounced. This is interesting as it has been proposed that impaired epithelial damage repair mechanisms are important drivers in asthma development \[[@C10]\]; however, very little is known regarding the natural origin of asthma development. Furthermore, P[avlidis]{.smallcaps} *et al*. \[[@C11]\] presented a follow-up study from the U-BIOPRED group at this year\'s European Respiratory Society (ERS) Congress which aimed to explore the enrichment of ILC1, ILC2 and ILC3 activation signatures in asthmatic transcriptomic samples. From this study, they conclude that a neutrophilic severe asthma phenotype was characterised by Group 1 ILC activation, associated with inflammasome, interferon-γ (IFN-γ) and tumour necrosis factor (TNF), which may reflect an antimicrobial response and contribute to chronic inflammation and remodelling in severe asthma.

Respiratory syncytial virus (RSV) and rhinovirus infections are major causes of bronchiolitis and pneumonia and are strongly associated with asthma exacerbations \[[@C12], [@C13]\]. Wheezing in response to viral infections correlates to asthma development in children \[[@C14], [@C15]\] and, while the majority children who wheeze upon viral infection recover without any enduring effects, a proportion of children with wheeze will develop asthma later in life \[[@C16], [@C17]\]. Despite strong evidence from longitudinal studies, it is not known how viral infections during early childhood are connected to the development of asthma \[[@C16], [@C17]\]. However, two concepts have emerged to explain why asthmatic patients are more sensitive to viral infections: 1) an exaggerated Type 2 T-helper cell (Th2) immune response towards viruses with increased levels of interleukin (IL)-4, IL-5 and IL-13 cytokines, and 2) a deficient anti-viral response primarily explained by impaired production of Type I and Type III IFNs \[[@C12]\]. Several *in vivo* and *in vitro* studies in human airway cells and murine models have shown a deficiency in IFN production in response to viral infection, a trend which is especially pronounced in severe asthmatic disease (see E[dwards]{.smallcaps} *et al.* \[[@C18]\]). Furthermore, the risk of developing asthma is increased with frequent viral-induced bronchiolitic episodes in combination with allergic sensitisation to airborne allergens \[[@C19]\]. R[ubner]{.smallcaps} *et al*. \[[@C20]\] showed in a recent study that the age of sensitisation (age \<1 year) and rhinovirus infection (but not RSV) was important for asthma development by adolescence. It has furthermore been reported that rhinovirus causes amplified release of double stranded DNA in individuals with asthma undergoing rhinovirus-induced asthma exacerbations and that the levels correlated with both symptom severity during exacerbation and rhinovirus-induced release of Type 2 cytokines \[[@C21]\]. In a study by D[anov]{.smallcaps} *et al*. \[[@C22]\], which was presented at this year\'s ERS Congress, the impact of an asthmatic background on the anti-viral and pro-inflammatory immune response was investigated in precision-cut lung slices (PCLS) of house dust mite (HDM)-sensitised mice. The authors showed that the HDM-induced allergic inflammation was maintained *ex vivo* in the PCLS and led to a reduced immune response to rhinovirus infection, as shown by decreased secretion of IFN-γ, IFN-γ-inducible protein 10 (IP-10) and IL-17A in response to HRV1B infection. Interestingly, Th2 cytokine IL-4 was further induced in rhinovirus-infected PCLS of HDM-sensitised mice.

A compelling amount of data now points towards a miscommunication between the innate and adaptive immune response towards viruses in asthmatic patients. Recent data has shown that, upon damage, epithelial cells release the alarmin IL-33 and data from genome-wide association studies has implicated IL-33 in the pathobiology of allergic diseases \[[@C23], [@C24]\]. At the ERS Congress this year there were several abstracts related to the role of IL-33 in asthma pathology (see R[avanetti]{.smallcaps} *et al*. \[[@C25]\], H[accuria]{.smallcaps} *et al*. \[[@C26]\] and P[erkins]{.smallcaps} *et al*. \[[@C27]\]). Higher levels of IL-33 have been found in subjects with severe asthma when compared with healthy controls \[[@C28]\]. The increased levels of IL-33 might be important since it can promote both innate and adaptive immune responses and can influence the cross-talk between these two arms of immune defense \[[@C29], [@C30]\]. In line with this, L[ynch]{.smallcaps} *et al*. \[[@C31], [@C32]\] reported that IL-33 can suppress innate anti-viral immune defense which in turn results in increased viral burden, airway smooth muscle hyperplasia and Th2 inflammation. A sequential study presented by U[pham]{.smallcaps} *et al.* \[[@C33]\] was aimed at examining the mechanisms involved and especially the two chains of the IL-33 receptor (IL-1 receptor like 1 (IL1RL, also known as ST2) and IL-1 receptor accessory protein (IL1RAP)). Peripheral blood mononuclear cells (PBMC) obtained from mild/moderate asthmatics and healthy donors were exposed to IL-33 and activated with rhinovirus. In asthmatic patients, rhinovirus alone or in combination with IL-33 induced significantly greater upregulation of ST2 mRNA expression than in healthy participants but had no effect on IL1RAP expression. The results were confirmed using flow cytometry and the increase was due to enhanced ST2 expression on ILC2s and T-lymphocytes. These findings suggest there is dysregulation of ST2 in asthma and provide a mechanism by which rhinovirus infections might exacerbate Type 2 inflammation.

Taken altogether, asthma is a very heterogeneous disease with specific gene patterns that, with increasing knowledge, will enable a more thorough stratification of asthmatic phenotypes. It is now vital that these phenotypes be linked to biological endotypes, where studies of the effects of biological treatments will be of great importance. The aforementioned studies further stress the notion that the complex interplay between viral infection and allergen exposure is important for the onset and progression of asthmatic disease. Difficult-to-treat patients that are unresponsive to conventional therapy would most likely benefit greatly from a thorough phenotyping and endotyping of their pathophysiology, with the ultimate goal of administering more specialised and personalised medication.

Chronic obstructive pulmonary disease {#s2}
=====================================

Pharmacological treatment of chronic obstructive pulmonary disease (COPD) aims to reduce symptoms, frequency and severity of exacerbations, to improve exercise tolerance and health status, and also to delay disease progression and death \[[@C34]\]. While there is still no conclusive evidence from clinical trials indicating that any of the existing COPD medications modify disease progression, there is fast-accumulating evidence on how to optimise symptom control and exacerbation prevention.

First, several trials assessing triple therapy, inclusive of a long-acting β-2 agonist, a long-acting antimuscarinic and an inhaled corticosteroid in a single device were presented. The FULFIL trial compared the triple combination of fluticasone furoate, umeclidinium and vilanterol against the combination of budesonide and formoterol in a 24-week randomised trial involving 1810 patients. It demonstrated the superiority of the triple combination with regards to spirometry, frequency of exacerbations, frequency of pneumonias, quality of life (QoL) and time to clinically important deterioration (CID, a composite measure of lung function, health status and exacerbation). The median time to first CID was 169 days for the triple combination *versus* 31 days for the long-acting β-agonist (LABA)/inhaled corticosteroid (ICS) combination \[[@C35], [@C36]\]. However, this study can be criticised for comparing a triple combination *versus* an ICS/LABA combination, rather than a single dose triple combination *versus* separate devices, which would have been more informative. Such an intervention was evaluated by the TRINITY trial \[[@C37]\] which compared the fixed triple combination of beclometasone dipropionate, formoterol fumarate and glycopyrronium bromide against the open triple combination of beclometasone dipropionate and formoterol fumarate plus tiotropium, or tiotropium alone, in a 52-week randomised controlled trial involving 2691 patients. The fixed triple combination was found to be superior to the long-acting muscarinic antagonist (LAMA) and to be non-inferior to the open triple combination with regards to frequency of moderate-to-severe exacerbations, time to first CID, spirometry and adverse effects \[[@C38]\]. Use of triple combination therapy is currently only recommended for Global Initiative for Chronic Obstructive Lung Disease (GOLD) Group D patients under current GOLD guidelines \[[@C34]\]. However, a *post hoc* analysis of the TRINITY and TRILOGY \[[@C39]\] trials this year has assessed the impact of fixed triple combination therapy *versus* LABA/ICS or LAMA therapy in Group B patients and found a significant decrease in the frequency of exacerbations \[[@C40]\].

Dual bronchodilation has also received a lot of attention this year. The FLAME trial, a 52-week trial involving 3362 patients with COPD and a history of at least one moderate or severe exacerbation during the preceding year, compared a fixed combination of indacaterol/glycopyrronium (LABA/LAMA) against salmeterol/fluticasone (LABA/ICS) and demonstrated the superiority of the LABA/LAMA combination *versus* the LABA/ICS combination with regards to exacerbations, lung function and QoL \[[@C41]\]. Several *post-hoc* analyses from the FLAME trial were presented this year, evaluating more domains and confirming the superiority of the LABA/LAMA combination. The number needed to treat (NNT) to avoid a moderate or severe COPD exacerbation (per year) was estimated to be 4.76 patients with dual bronchodilation. In addition, the NNT to keep a patient with at least one exacerbation in the preceding year free of exacerbations was 15 \[[@C42]\]. Indacaterol/glycopyrronium was also shown to be useful in reducing the risk of CID, defined as a decrease of 100 mL in forced expiratory volume in 1 s (FEV~1~) or an increase of four points on the St George\'s Respiratory Questionnaire (SGRQ). Indacaterol/glycopyrronium reduced the risk of first and sustained CID by approximately 30% *versus* salmeterol/fluticasone, as presented by A[nzueto]{.smallcaps} *et al.* \[[@C43]\]. Further analyses confirmed the safety of dual bronchodilation as it was associated with fewer respiratory-related adverse events of special interest, including but not limited to pneumonia, compared with salmeterol/fluticasone \[[@C44]\]. The cost effectiveness of indacaterol/glycopyrronium compared to treatment with salmeterol/fluticasone was also assessed in a real-life context, in the ARCTIC Swedish cohort study of 18,586 subjects over 3 years. Dual bronchodilation was associated with lower total direct costs (a saving of 732 euro per patient) and better outcomes (0.008 quality-adjusted life-years and 0.005 life-years gained).

The ACLIFORM and AUGMENT trials compared another dual bronchodilator (aclidinium/formoterol) against its monocomponents or a placebo, in 3394 maintenance treatment naïve patients with moderate or severe COPD over a 24-week period and in a double-blinded fashion. Pooled studies from these trials have demonstrated the superiority of aclidinium/formoterol *versus* its monocomponents or a placebo with regards to symptoms, QoL, frequency of exacerbations and use of relief medications \[[@C45], [@C46]\]. ACTIVATE, an 8-week trial of 267 patients also found that aclidinium/formoterol significantly improved physical activity compared to a placebo at 4 and 8 weeks \[[@C47]\].

The use of a fixed-dose dual bronchodilator was also evaluated in 4117 COPD patients under real-life conditions in the DACCORD study \[[@C48]\]. Patients were recruited following a change in their maintenance treatment by their clinicians (as indicated by a non-interventional study) and the exacerbation frequency of patients who received a LABA/LAMA combination *versus* other treatments was compared \[[@C49]\]. Dual bronchodilation was correlated with significantly fewer exacerbations amongst those patients who had at least one exacerbation in the 6 months preceding recruitment.

Finally, in an interesting animal study, G[osset]{.smallcaps} *et al.* \[[@C50]\] assessed the effect of prophylactic administration of flagellin, a toll-like receptor 5 (TLR5) agonist, in mice with COPD. Mice treated with flagellin were found to have significantly lower bacterial load in bronchoalveolar lavage (BAL), suggesting a potential protective effect of flagellin against bacterial infection or colonisation. This opens a new therapeutic line in terms of the stimulation of the innate immune response to prevent COPD exacerbations.

Overall, data are fast accumulating which support the effectiveness of bronchodilators, inhaled steroids and combination therapies, which clearly improve the health status and QoL of patients while decreasing the frequency of exacerbations. Unfortunately, there are still significant challenges ahead as none of the available treatments can halt or delay disease progression or prolong survival. In addition, our expanding understanding of COPD heterogeneity and clinical phenotypes has only now started to be translated into the development of better, targeted treatments.

Novel monoclonal antibodies in asthma and COPD {#s3}
==============================================

Asthma and COPD are common chronic inflammatory airways diseases that affect an estimated 700 million people worldwide \[[@C51], [@C52]\]. Despite taking high dose inhaled and often daily oral steroid treatments, approximately 5--10% of patients with asthma have severe asthma \[[@C53]\] and between 30--40% of patients with COPD have recurrent moderate to severe exacerbations on inhaled triple therapy \[[@C54]\], even if there is an increasing body of evidence for positive results in patients\' QoL. This results in a high burden of disease on QoL and employment, as well as pressure on healthcare services. Over the last 20 years, there has been a focus on treating uncontrolled patients by understanding the underlying pathological mechanisms which lead to such complex heterogeneous airways diseases. Mechanistic studies have highlighted the role of Type 2 inflammatory cytokines (IL-4, IL-5, IL-9 and IL-13) and airway eosinophils as important biomarkers to target in asthma; however, only recently has evidence emerged showing the limited benefits of such a targeted strategy in COPD \[[@C55]\]. A potential limitation in studies targeting IL-5 or eosinophils is that such drugs largely benefit patients who demonstrate an eosinophilic phenotype, hence excluding a large proportion of subjects. However, novel data has shown the importance of inflammatory cytokines secreted from the airway epithelium in orchestrating and activating Type 2 inflammation \[[@C56]\] and Group 2 ILCs (ILC2s) \[[@C57]\]. These are collectively known as the epithelial "alarmins" and currently include IL-33, IL-25 and thymic stromal lymphopoietin (TSLP). The latter has emerged as an important target for asthma, irrespective of allergic or eosinophilic status. Here we focus on data presented at the ERS International Congress 2017 for tezepelumab (in patients with uncontrolled asthma) and mepolizumab (for eosinophilic COPD), as they represent an advancement in both our current understanding and our future treatment options.

TSLP is produced from the airway epithelium in response to a wide variety to external stimuli, such allergens and viruses, and has the ability to act as an "epithelial alarmin" by activating Type 2 inflammation *via* activation of dendritic cells, ILC2s, T-cells and B-cells, resulting in an increase in airway inflammatory cytokines, particularly IL-4, IL-5 and IL-13. An earlier proof of concept study showed the efficacy of tezepelumab in reducing the early and late asthmatic responses in an allergen challenge model, with profound reductions in both serum and sputum eosinophils \[[@C56]\]. However, most asthma exacerbations occur due to viral exacerbations and all patients in the allergen challenge model were steroid naïve and well controlled. As such, the rationale for this larger multicentre, placebo-controlled, double-blind follow up study was to test the efficacy of tezepelumab in a much broader population of uncontrolled moderate to severe asthma patients unselected for serum eosinophils \[[@C58]\]. Over a 52-week period, tezepelumab (70 mg or 210 mg every 4 weeks, or 210 mg every 2 weeks) reduced exacerbation rates by 61%, 71% and 66% more than a placebo, respectively, and, most importantly, this improvement was seen irrespective of blood eosinophil count at baseline. There were significant improvements in pre-bronchodilator FEV~1~, asthma control and reductions in exhaled nitric oxide fraction (*F*~eNO~) and serum IgE. This suggests that the rationale of inhibiting the inflammatory cascade higher up the pathway is effective at augmenting a wider range of Type 2 inflammatory mediators irrespective of allergic or eosinophil status. These findings make the results of this study different to those observed previously (targeting IL-5 or its receptor subunit only). The only caveats to this study were that the majority of patients were recruited from Eastern Europe and Ukraine, 90% were Caucasian and there was a large placebo effect. Further Phase 3 studies in different healthcare settings and with broader ranges of ethnicities would add value to these initial results.

Although the targeting of eosinophils has most often been associated with treating asthma, there have been important observations to suggest a role in COPD. The ECLIPSE study showed that nearly 40% of patients had persistently raised serum eosinophils (≥2%), which was associated with an increased risk of exacerbations, but were highly responsive to corticosteroids \[[@C59]\]. However, the side-effects profile, particularly the increased risk of pneumonia, has more recently led to a renewed emphasis on steroid reduction and alternative treatment strategies. The rationale to this study was rooted in observing an association between lower exacerbation rates than placebo in two mepolizumab in severe asthma studies with some features of COPD (the MENSA and DREAM studies). The objective of this study was to evaluate the efficacy and safety of subcutaneous mepolizumab, as compared with placebo, as an additional treatment to inhaled triple therapy in those COPD patients with an eosinophilic phenotype and a history of moderate or severe exacerbations \[[@C60]\]. An eosinophilic phenotype was defined as ≥150 cells·mm^−3^ at screening or ≥300 cells·mm^−3^ in the previous year and moderate exacerbations were defined as ≥2 episodes requiring steroids±antibiotics (and as severe if leading to hospitalisation). The data presented demonstrated an 18% reduction in combined moderate and severe exacerbations only in those patients defined as having an eosinophilic phenotype, with the greatest effect seen in those with the highest eosinophil counts. However, no difference was found in hospitalisations, emergency department visits, FEV~1~ or QoL endpoints, nor is there any data currently available for the possibility of steroid dose reduction as has been seen in asthma. The implication of these results is to potentially use serum eosinophils as a biomarker to identify those most likely to benefit from such immune therapy. However, this needs to be balanced with the fact that there was a large improvement in exacerbations in the placebo group likely related to improved adherence during the clinical trial. This is not unusual for most trials in COPD and asthma but raises the question of the need for such expensive treatment in a resource-stretched healthcare system.

Overall, studies involving monoclonal antibodies in patients with asthma and now COPD have improved our understanding of airway pathobiology; however, applicability, long term safety and cost effectiveness for a large (and broader) population will ultimately dictate eligibility and access to such treatments.

Non-cystic fibrosis bronchiectasis {#s4}
==================================

Bronchiectasis is a disease accompanied by irreversible enlargement of the airways and is characterised by ineffective mucociliary clearance and excessive inflammation. The inflammation is not just excessive it is also ineffective, as it causes airway destruction and distortion which leads to ineffective mucus clearance. Ineffective mucus clearance in turn leads to bacterial colonisation, which itself enhances inflammation-the so called "vicious cycle" of bronchiectasis. Pseudomonas bacteria frequently colonise the airways of patients with bronchiectasis and this is associated with exacerbations and disease severity. This year, C[halmers]{.smallcaps} *et al.* \[[@C61]\] further evaluated the impact of Pseudomonas colonisation on the outcomes of bronchiectasis using data from the Facilitating Research Into Existing National Datasets (FRIENDS) cohort, a historical dataset integrating national registries of bronchiectasis from the past decade with the intention of giving a clear picture of bronchiectasis management and outcomes and including 2596 patients with high-resolution computed tomography (HRCT) confirmed bronchiectasis. Researchers found Pseudomonas colonisation to be associated with worse symptoms, radiologic severity and more frequent exacerbations (median: three per year). Importantly, they also demonstrated that colonised patients were at twice as high a risk of death.

Furthermore, S[mith]{.smallcaps} *et al.* \[[@C62]\] identified a novel biomarker of disease severity starting from the observation that most patients with bronchiectasis are women. More specifically, they found high levels of pregnancy zone protein (PZP, an oestrogen-regulated antiprotease) in the sputum of patients with bronchiectasis and explored its prognostic value in 80 patients. PZP was strongly correlated with bronchiectasis severity index, SGRQ, level of breathlessness and Pseudomonas infection.

At the ERS Congress, several high quality studies focused on bronchiectasis management, which is complex and needs to cover the management of both acute exacerbations and stable disease (including exacerbation prevention). During stable disease, control of microbial load decreases inflammation and mucus production and delays subsequent exacerbations. Inhaled antibiotic therapy includes colistin and gentamycin, and there are ongoing trials with ciprofloxacin and levofloxacin. Indeed, F[oehlich]{.smallcaps} *et al*. \[[@C63]\] reported in Milan on a *post-hoc* analysis of two 48-week trials involving 148 participants colonised by Pseudomonas, which demonstrated that long-term, intermittent use of ARD-3150, a combination of liposome-encapsulated and free ciprofloxacin, significantly decreased the frequency of pulmonary exacerbation in bronchiectasis patients, regardless of the Pseudomonas\' susceptibility to ciprofloxacin.

Macrolide antibiotics also possess potent anti-inflammatory effects \[[@C64]\]. In cases of rhinovirus infection, macrolides increase the release of IFN and decrease viral load \[[@C65]\]. Many multicentre trials have investigated macrolide use in bronchiectasis and, while they significantly decrease exacerbation rate and increase the time to first exacerbation, they do not influence FEV~1~. There is however an improvement in QoL based on the SGRQ \[[@C66]--[@C70]\]. Macrolides suppress systemic inflammation and C-reactive protein (CRP) decreases along with sputum and peripheral neutrophil counts. If exacerbation rate is more than three per year then the use of macrolides is beneficial. In accordance with these results MERTSCH *et al.* \[[@C71]\] found that 33% of patients in a German cohort were on azithromycin maintenance therapy, while D[har]{.smallcaps} *et al.* \[[@C72]\] showed that 55.1% of patients who were on antibiotic treatment in India received low-dose macrolides (31% with azithromycin).

The role of long-term administration of antibiotics in patients with bronchiectasis and frequent exacerbation is indisputable. However, further studies are required to compare the efficacy and safety of different treatment regimes (different antibiotics, route of administration and frequency *etc.*). Importantly, bronchial hygiene and mucolytic treatments are effective and safer and need to be prioritised.

Chronic cough {#s5}
=============

Cough is the primary reason for patients to visit a physician \[[@C73]\] and yet it remains an unmet medical need. Chronic cough, which can occur as a result of respiratory disease but can also be idiopathic in nature \[[@C74]\] can severely lower the QoL of sufferers \[[@C75]\]. In the year preceding March 2013, over \$156 million was spent in the UK on cough medications \[[@C76]\] despite the fact that they have been shown to be ineffective. Therefore, there is an urgent requirement for new, safe and effective therapies, and the clinical problem of cough was highlighted at the ERS Congress where there was a "meet the expert" seminar on the topic. At this event, Professor Alyn Morice talked clinicians through the underlying mechanisms, diagnosis and treatment of patients with refractory chronic cough.

Cough is a reflex event triggered following activation of airway sensory nerves housed within the vagus nerve \[[@C77]\]. Sensory nerve terminals are distributed throughout the airways and express a number of ion channels and receptors that could represent novel targets for treatment. To date, the only ion channel antagonist that has shown efficacy in refractory chronic cough is P2X2/3 antagonist MK-7264 (formerly AF-219), which significantly inhibited daytime objective cough frequency by 75%. This indicates that the endogenous ligand of this ion channel, ATP, is likely to play a role in refractory chronic cough \[[@C78]\]. Two clinical studies highlighted at the ERS Congress showed further results with this compound. S[mith]{.smallcaps} *et al.* \[[@C79]\] presented the results of a double-site, 12-week parallel group study with MK-7264 in patients with refractory chronic cough. A total of 253 patients were given a placebo or the P2X3 antagonist MK-7264 (one of three doses: 7.5 mg, 20 mg or 50 mg, all of which were lower than that used in the original study where most patients experienced dysgeusia) and awake cough frequency and 24-h cough frequency were assessed. Despite a large placebo effect, both of these end points were significantly reduced following treatment with the 50 mg dose of MK-7264, indicating that this compound is efficacious at more well-tolerated doses. M[orice]{.smallcaps} *et al.* \[[@C80]\] also presented a study utilising this compound. Their study looked at evoked tussive responses to ATP, citric acid, capsaicin or distilled water (fog) following treatment with MK-7264 or a placebo in healthy controls and patients with refractory chronic cough. All tussive challenges evoked a cough response in chronic cough patients but only cough responses to ATP and fog were inhibited with the antagonist, indicating successful target engagement by the compound. Another study indicated that activation of airway sensory nerves by hypo-osmolar solutions such as distilled water was through activation of the ion channels TRPV4 and TRPM3, which release ATP to activate P2X3 \[[@C81]\].

Other notable studies investigated other receptors which may be involved in the cough response. D[icpinigatis]{.smallcaps} *et al.* \[[@C82]\] looked at the effect of the α7 nicotinic receptor in guinea pig cough. The authors observed that in healthy non-smoking individuals, e-cigarettes containing nicotine had a marked antitussive effect and therefore hypothesised that nicotine could inhibit cough. In a guinea pig model, it was indicated that nicotine and selective agonists of the α7 nicotinic receptor inhibited cough induced by citric acid and therefore the antitussive effects of e-cigarettes were likely to be through the α7 nicotinic receptor. A further study by W[ortley]{.smallcaps} *et al.* \[[@C83]\] highlighted the inhibitory effects of agonists of the EP2 and EP4 receptors on TRPV1 induced responses. EP2 and EP4 are receptors for the inflammatory mediator prostaglandin E2, which has been shown to have a variety of beneficial and detrimental effects in the airways. EP3 evokes cough and EP2 and EP4 have protective bronchodilator and anti-inflammatory effects; however, these inhibitory effects are lost following cigarette smoke exposure indicating that prostanoids could play a role in cough in diseases such as COPD.

Overall, the novel studies showcased at the ERS Congress indicate that the search for an effective treatment for the troublesome problem of chronic refractory cough is underway. Perhaps the most promising is the P2X3 antagonist MK-7264, which has now shown efficacy in two clinical trials along with successful target engagement. In addition, further pre-clinical studies have highlighted other potential targets for the treatment of refractory chronic cough.

Conflict of interest: R. Gosens reports receiving grants from Chiesi Farmaceutici, Boehringer Ingelheim and Aquilo BV, outside the submitted work. I. Satia reports receiving a BMA James Trust Award, personal fees from educational talks for general practitioners, travel awards and an ERS Respire 3 Fellowship Award, outside the submitted work. O. Usmani reports receiving personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, NAPP, Mundipharma, Sandoz, Cipla, Takeda, Zentiva and Trudell Medical, and grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Prosonix, Edmond Pharma, Cipla, NAPP, Mundipharma, Sandoz and Aerocrine, outside the submitted work.
